Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Urine Test Could Predict Outcome of Cartilage Transplant Surgery

By HospiMedica International staff writers
Posted on 18 Sep 2025

Cartilage transplant surgery provides an alternative to artificial joint replacements by using donor tissue to restore knee function. More...

While many patients benefit, outcomes can vary, leaving uncertainty about who is most likely to succeed. Now, new research has revealed that urine samples contain protein biomarkers that may help predict surgical results, offering a noninvasive way to guide treatment decisions before performing any invasive procedures.

A team of researchers at the University of Missouri (Columbia, MO, USA) has been investigating biological markers to predict the outcomes of osteochondral allograft transplantation, a knee procedure that replaces damaged cartilage with healthy donor tissue. This approach preserves the patient’s natural joint rather than relying on artificial materials. The team analyzed protein biomarkers in urine, which fluctuate with age and other factors, making them dynamic indicators for surgical candidacy that can change over time.

The study identified nine proteins strongly associated with poor outcomes after surgery. Patients with elevated levels of these proteins were significantly less likely to experience success with the transplant. The findings, published in The Journal of Knee Surgery, demonstrate the potential for urine-based biomarker testing to guide patient selection and improve precision in orthopedic medicine.

This discovery could empower patients and clinicians to make more informed choices about the timing and type of knee surgery. Because biomarker levels are not fixed, patients who are not initially good candidates may later qualify, enabling flexible and personalized care. The research marks a shift from optimizing the surgery itself to optimizing the patient for surgery, laying the groundwork for more tailored orthopedic solutions.

“We’ve spent 15 years focused on optimizing the surgery for the patient, and now we are focusing on optimizing the patient for the surgery. These protein biomarkers give us important clues as to who can best benefit from this particular surgery,” said Jimi Cook, DVM ‘94, PhD ‘98, who led the research team. “By better understanding which protein biomarkers are linked with unsuccessful outcomes, we can determine the best data-driven treatment plan for each individual with knee pain before doing any invasive procedures.”

Related Links:
University of Missouri


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Syringes
Prefilled Saline Flush Syringes
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.